Search Results
62 Results for 'Oncology'
PAGE 2 OF 3
Technology
Radiohalogenated Agents For In Situ Immune Modulated Cancer Vaccination
A method of treating a malignant solid tumor in a subject is disclosed herein. The method includes the steps of administering to the subject an immunomodulatory dose of a radiohalogenated compound tha...
Learn More
Learn More
Jamey Weichert, Paul Sondel, Anatoly Pinchuk, Zachary Morris, Mario Otto, Bryan Bednarz | P160396US02
Technology
Targeted Radiotherapy Chelates For In Situ Immune Modulated Cancer Vaccination
The disclosed method of treating a malignant solid tumor in a subject includes the steps of administering to the subject an immunomodulatory dose of a radioactive phospholipid metal chelate compound t...
Learn More
Learn More
Jamey Weichert, Paul Sondel, Anatoly Pinchuk, Zachary Morris, Mario Otto, Bryan Bednarz, Peter Carlson | P160397US02
Technology
Nanoengineered Surfaces For Cancer Biomarker Capture
Described herein is cancer biomarker, e.g., a vesicle, capture surface that includes a substrate, a first plurality of nanoparticles attached to the substrate; a plurality of bifunctional tethers, whe...
Learn More
Learn More
Seungpyo Hong, Michael Poellmann | P180105US02
Technology
Antibodies Targeting Glioblastoma Stem-Like Cells And Methods Of Use Thereof
The present invention provides antibodies that target glioblastoma stem-like cells and methods and kits for their use.
Learn More
Learn More
Eric Shusta, Michael Zorniak, Paul Clark, Yongku Cho, Benjamin Umlauf, John Kuo | P180018US02
Technology
Biemamides And Related Scaffolds As Inhibitors Of Transforming Growth Factor-Beta Signaling
The present technology provides an isolated compound of Formula I, compositions including such compounds, methods of inhibiting TGF-β signaling and/or TGF-β induced epithelial mesenchymal transition...
Learn More
Learn More
Timothy Bugni, Fan Zhang, Douglas Braun, Gene Ananiev, F. Michael Hoffmann | P180361US02
Technology
Generation Of Hematopoietic Progenitor Cells From Human Pluripotent Stem Cells
Methods for generating and using hematopoietic progenitor cells are described.
Learn More
Learn More
James Thomson, Jue Zhang | P180326US02
Technology
Synthesis Of Small Molecule Histone Deacetylase 6 Degraders, Compounds Formed Thereby, And Pharmaceutical Compositions Containing Them
Histone deacetylase (“HDAC”)-selective inhibitors covalently bonded to a linker covalently bonded to an E3 ubiquitin ligase ligand, and salts thereof; pharmaceutical compositions containing them; ...
Learn More
Learn More
Weiping Tang, Ka Yang, Hao Wu | P180321US03
Technology
Stereocomplex Of Oligolactic Acid Conjugates In Micelles For Improved Physical Stability And Enhanced Antitumor Efficacy
The present technology relates generally to oligolactic acid conjugates and stereocomplexes of cortjugates of gemcitabine and gemcitabine derivatives, micelle compositions containing such conjugates...
Learn More
Learn More
Glen Kwon, Yu Tong (Tony) Tam | P180209US02
Technology
Oligolactic Acid-Paclitaxel and Oligolactic Acid-Docetaxel Prodrugs for Injection
PTX, DTX, rapamycin and selumetinib are potent chemotherapeutic agents useful in the treatment of a variety of cancers. Due to their limited water solubility, PTX and DTX are commonly formulated for...
Learn More
Learn More
Glen Kwon, Yu Tong (Tony) Tam | P160169US03
Technology
Bacterial Membrane Nanoparticles as an Immunotherapy System for Cancer Treatment
Cancer immunotherapy – a therapy that stimulates and employs the body’s own immune system – is one of the most promising new approaches for treating cancer. Despite its tremendous potential, it ...
Learn More
Learn More
Shaoqin Gong, Zachary Morris, Mingzhou Ye, Ravi Patel, Paul Sondel | P180331US02
Technology
Phospholipid Ether Analogs for Treating and Imaging Pediatric Solid Tumors
Currently there is only one well-studied and established tumor-targeting radioactive agent in pediatric oncology (131I-MIBG), which only targets neuroblastoma and other rare neuroendocrine tumors. It ...
Learn More
Learn More
Mario Otto, Bryan Bednarz, Jamey Weichert, Dana Baiu | P160325US02
Technology
Novel Small Molecule SIRT6 Activators/Inhibitors
The epigenetic modifier SIRT6 is of the sirtuin class of proteins. In transgenic mice, increased SIRT6 expression lowers LDL and triglyceride levels, improves glucose tolerance and increases mitochond...
Learn More
Learn More
John Denu, Weiping Tang | P160306US01
Technology
Synstatin “SSTNI/V” Disrupts Cancer Growth
Leading UW–Madison oncologists previously showed that the matrix receptor syndecan-1 (Sdc1/CD138) – a matrix receptor highly expressed in multiple myeloma – captures and activates multiple cell ...
Learn More
Learn More
Alan Rapraeger, DeannaLee Beauvais, Oisun Jung | P160224US02
Technology
Methods and Compositions for Treating Prostate Cancer Using DNA Vaccines
Prostate cancer is a significant health risk for men over the age of 50 and currently is a pervasive health threat with as many as 200,000 new cases diagnosed each year in the US alone. At presen...
Learn More
Learn More
Douglas McNeel, Brian Olson | P05235US
Technology
TLR Agonists for Reducing Activation-Induced PD-1 Expression on T Cells, Improved Anti-Tumor Response
Current anti-cancer DNA vaccines are safe and immunologically effective, but would be still more effective if they could elicit a stronger anti-tumor response and require fewer administrations. For th...
Learn More
Learn More
Douglas McNeel, Christopher Zahm | P170048US02
Technology
Combinatorial Androgen Deprivation With An Androgen Receptor Vaccine
The androgen receptor (AR) is a steroid hormone receptor that plays a crucial role in the development of normal prostate tissue, as well as in the progression of prostate cancer. Patients with metasta...
Learn More
Learn More
Douglas McNeel, Brian Olson | P160108US02
Technology
Novel Analogs of Podophyllotoxin May Treat Cancer and Viral Infections
Podophyllotoxin is a natural product derived from a plant. Although two clinically useful glycosylated analogs have been developed for treating cancer, podophyllotoxin is difficult to synthesize, hind...
Learn More
Learn More
Jon Thorson, James Watson, Jr. | P08343US
Technology
Inhibiting Metadherin/SND1 Interaction to Treat Cancer
Metadherin (MTDH; also called AEG1 or LYRIC) is a pro-metastasis gene implicated in many types of cancer. The gene is overexpressed in more than 40 percent of primary tumors and is linked to breast ca...
Learn More
Learn More
Yongna Xing, Liling Wan, Yibin Kang, Feng Guo | P140424US02
Technology
Analogs of Diptoindonesin G for Breast Cancer Drug Development
The natural product diptoindonesin G (Dip G) was first isolated in 2009 from the tree bark of Hopea mengarawan. It has shown antiproliferation effects in murine leukemia as well as immunosuppressant a...
Learn More
Learn More
Wei Xu, Weiping Tang, Jitian Liu, Jill Kolesar | P170010US02
Technology
Warfarin Promoter
Warfarin is a “first-generation” anticoagulant that has been widely used as a multiple feeding rodenticide for more than 60 years. The prolonged use of warfarin as a rodenticide has, according to ...
Learn More
Learn More
David Lewis, Michael Caldwell | T100001US02
Technology
Increasing Red Blood Cell Production
Maintaining an adequate supply of oxygen to tissue is necessary for survival. The oxygen-carrying capacity of blood is governed by the concentration of red blood cells (erythrocytes). It is critical t...
Learn More
Learn More
Emery Bresnick, Yoon A Kang, Skye McIver | P130326US02
Technology
Treating Iron Overload with Block Copolymers
Iron overload or hemochromatosis is a disease marked by an accumulation of iron in the blood. It typically occurs in subjects (e.g., anemia patients) receiving chronic infusions of red blood cells. Th...
Learn More
Learn More
May Xiong, Zhi Liu, Yan Wang | P140395US02
Technology
Use of Peptides of Syndecan-1 to Inhibit Angiogenesis
Syndecans, a highly conserved family of four transmembrane heparan sulfate proteoglycans, bind a variety of extracellular matrix ligands, including fibronectin, laminin and vitronectin. Syndecan-1 ser...
Learn More
Learn More
Alan Rapraeger, DeannaLee Beauvais | P06390US02
Technology
Provoking Anti-Tumor Immune Response with Rhamnose
One promising approach to cancer treatment is to leverage the immune system. Specifically, tumors can be ‘tagged’ with foreign antigens that attract the body’s defensive antibodies. The antibodi...
Learn More
Learn More
Laura Kiessling, Rachael Sheridan, Jonathan Hudon | P120290US02
Technology
Protecting Ovaries from Chemotherapy Damage Using Proteasome Inhibitors
Primary ovary insufficiency (POI) caused by chemotherapy treatment is experienced by many cancer survivors, including up to 40 percent of reproductive-age breast cancer survivors and eight percent of ...
Learn More
Learn More
Sana Salih, Elon Roti Roti | P130111US02